HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?

Laurie Townsend; Diane J Madlon-Kay

HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?

Laurie Townsend, Diane J Madlon-Kay

Family Medicine and Community Health (Twin Cities)

Research output: Contribution to journal › Article › peer-review

Abstract

Possibly. Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone. Studies showing an increase in catastrophic events had serious methodologic issues. A large surveillance study is ongoing.

Original language	English (US)
Pages (from-to)	370-371
Number of pages	2
Journal	The Journal of family practice
Volume	64
Issue number	6
State	Published - Jun 1 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

OpenUrl availability

Full text

Cite this

@article{ddeb2d0711804483bce6c63bbb6ea37b,

title = "HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?",

abstract = "Possibly. Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone. Studies showing an increase in catastrophic events had serious methodologic issues. A large surveillance study is ongoing. ",

author = "Laurie Townsend and Madlon-Kay, {Diane J}",

year = "2015",

month = jun,

day = "1",

language = "English (US)",

volume = "64",

pages = "370--371",

journal = "The Journal of family practice",

issn = "0094-3509",

publisher = "Appleton-Century-Crofts",

number = "6",

}

TY - JOUR

T1 - HelpDesk answers

T2 - is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?

AU - Townsend, Laurie

AU - Madlon-Kay, Diane J

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Possibly. Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone. Studies showing an increase in catastrophic events had serious methodologic issues. A large surveillance study is ongoing.

AB - Possibly. Long-acting β-2 agonists (LABAs) used in combination with inhaled corticosteroids (ICS) don't appear to increase all-cause mortality or serious adverse events in patients with persistent asthma compared with ICS alone. Studies showing an increase in catastrophic events had serious methodologic issues. A large surveillance study is ongoing.

UR - http://www.scopus.com/inward/record.url?scp=84942613696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942613696&partnerID=8YFLogxK

M3 - Article

C2 - 26172630

AN - SCOPUS:84942613696

SN - 0094-3509

VL - 64

SP - 370

EP - 371

JO - The Journal of family practice

JF - The Journal of family practice

IS - 6

ER -

HelpDesk answers: is it safe to add long-acting β-2 agonists to inhaled corticosteroids in patients with persistent asthma?

Abstract

UN SDGs

OpenUrl availability

Other files and links

Fingerprint

Cite this